Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6187)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Oct 6, 2022 (publication date) through Feb 9, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Li LJ, Zhang JY. Treatment of refractory/relapsed extranodal NK/T cell lymphoma with decitabine plus anti-PD-1: A case report. World J Clin Cases 2022; 10(28): 10193-10200 [PMID: 36246799 DOI: 10.12998/wjcc.v10.i28.10193] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Li LJ, Zhang JY. Treatment of refractory/relapsed extranodal NK/T cell lymphoma with decitabine plus anti-PD-1: A case report. World J Clin Cases 2022; 10(28): 10193-10200 [PMID: 36246799 DOI: 10.12998/wjcc.v10.i28.10193] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i28/10193.htm |
| Number | Citing Articles |
| 1 |
Jing Chen, Shan Zhang, Yi Zhao, Fang Zheng, Fanjun Cheng. Epstein-Barr virus: biology, pathogenesis and therapy of lymphomas. Discover Oncology 2025; 16(1) doi: 10.1007/s12672-025-03504-0
|
| 2 |
Yingfang Feng, Xia Liu, Jingwei Yu, Zheng Song, Lanfang Li, Lihua Qiu, Shiyong Zhou, Zhengzi Qian, Xianhuo Wang, Huilai Zhang. An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma. Expert Opinion on Biological Therapy 2025; 25(1): 9 doi: 10.1080/14712598.2024.2444400
|
| 3 |
|